Teraligen coated pills 5mg N50
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Alimemazine tartrate
Release form
Pills
Composition
1 tablet contains: Active substance: alimemazine tartrate 5 mg. Adjuvants: lactose, colloidal silicon dioxide, refined sugar (sucrose), wheat starch, tapioca starch, talc, magnesium stearate. Coat composition: hypromellose, macrogam 6000, ma dioxide, dye Osprey R110 pink, talc.
Pharmacological effect
Antipsychotic drug (neuroleptic). It has antihistamine, antispasmodic, serotonin-blocking, moderate alpha-adrenergic blocking, antiemetic, hypnotic, sedative and antitussive action. The antipsychotic effect is due to the blockade of the dopamine D2-receptors of the mesolimbic and mesocortical system. It has a low antipsychotic activity, therefore it is ineffective in acute psychotic states. Sedative action is due to the blockade of the adrenergic receptors of the reticular formation of the brain stem. The antiemetic effect is caused by the blockade of the dopamine Dg-receptor trigger zone of the vomiting center. in child, adolescent and gerontological practice.
Pharmacokinetics
Absorption: When ingestion is quickly and completely absorbed from the gastrointestinal tract. Cmax in plasma is observed after 1-2 hours. Distribution: Plasma protein binding of 20-30%. Metabolism: A metabolite is formed - sulfoxide. Excretion: Excreted as a metabolite with urine (70-80%) within 48 hours. T1 / 2 is 3.5-4 hours.
Indications
Neuroses and neurosis-like states of endogenous and organic genesis with a predominance of senesthopathic, hypochondriac, phobic and psycho-vegetative disorders. Psychopathies with asthenic and psycho-asthenic disorders. Anxious-depressive states in the framework of borderline and vascular diseases. Senesthopathic depressions. diseases. Sleep disorders of various genesis. Allergic reactions (symptomatic treatment).
Contraindications
Hypersensitivity. Angle glaucoma. Prostate gland hyperplasia. Severe liver and kidney diseases. Parkinsonism. Myasthenia syndrome. Syndrome. Simultaneous use of MAO inhibitors. Pregnancy. Breastfeeding period. Chronicle. 7 years of age.if in the history there are indications of complications in the use of drugs of the phenothiazine series. bladder neck obstruction, predisposition to urinary retention, epilepsy, open-angle glaucoma, jaundice, bone marrow function suppression, arterial hypotension.
Precautionary measures
The drug should be used with caution in chronic alcoholism, if there are indications of complications in the use of phenothiazine drugs, bladder neck obstruction, predisposition to urinary retention, epilepsy, open-angle glaucoma, jaundice, bone marrow suppression, arterial hypotension.
Use during pregnancy and lactation
The drug is contraindicated in pregnancy and during breastfeeding.
Dosage and administration
Inside The daily dose is divided into 3-4 doses. Adults - 5–10 mg / day (soporific effect); 60–80 mg / day (anxiolytic effect). In psychotic conditions - 0.2–0.4 g / day. Children from the age of 7 are prescribed according to the following scheme (depending on age and body weight): 2.5–5 mg / day (soporific effect); 5–20 mg / day (as a symptomatic treatment of allergic reactions); 20–40 mg / day (anxiolytic action). In psychotic states, it is possible to increase the daily dose to 60 mg / day.
Side effects
The drug is usually well tolerated. Side effects are extremely rare and are mild. From the nervous system drowsiness, lethargy, fatigue, occurring mainly in the first days of administration and rarely require discontinuation of the drug. paradoxical reaction (anxiety, agitation, “nightmarish” dreams, irritability). rarely - confusion, extrapyramidal disorders (hypokinesia, akathisia, tremor). more frequent sleep apnea, increased convulsive activity (in children). On the part of the sense organs, blurred visual perception (accommodation paresis), noise or tinnitus. On the side of the CVS dizziness, decrease in blood pressure, tachycardia. On the part of the digestive system, dry mouth, atony of gastrointestinal tract , constipation, loss of appetite. On the part of the respiratory system, dryness in the nose, throat, increase in viscosity of bronchial secretions. On the part of the urinary system, atony of the bladder, urinary retention. Other allergic reactions, inhibition of bone and cerebral blood effect, increased sweating, muscle relaxation, photosensitization.
Overdose
Symptoms: depression of consciousness, increased adverse reactions. Treatment: symptomatic.
Interaction with other drugs
Alimemazin enhances the action of opioid analgesics, hypnotics, anxiolytic (tranquilizers) and antipsychotic (neuroleptics) drugs, as well as drugs for general anesthesia, m-anticholinergic and antihypertensive drugs. It is necessary to adjust the dose of alimemazine with simultaneous use with the above-mentioned drugs. With simultaneous use of alimemazine with amphetamine derivatives, m-cholinomimetics, ephedrine, guanethidine, levodopa, dopamine, the action of the latter is weakened. CNS. With simultaneous use of alimemazine with antiepileptic drugs and barbiturates, the threshold for trial is reduced. road readiness (requires dose adjustment of the drug). With simultaneous use of alimemazine with beta-blockers, the concentration of the latter in plasma increases (possibly a pronounced decrease in blood pressure, arrhythmias). the use of alimemazine with tricyclic antidepressants and anticholinergic drugs increases the m-anticholinergic blocking activity with simultaneous use of alimemazine with MAO inhibitors and phenothiazine derivatives, there is an increased risk of arterial hypertension and extrapyramidal disorders (simultaneous use is not recommended). means enhanced manifestations of hepatotoxicity of the drug.
special instructions
With long-term treatment should be systematically carried out a complete blood count, to evaluate the function of the liver. Alimemazin can mask the ototoxic effect (tinnitus,dizziness) of jointly used drugs. In order to prevent distortion of skin scarification test results for allergens, the drug should be discontinued 72 hours before allergological testing. motor transport and control mechanisms. Against the background of drug treatment, one should not engage in activities requiring increased concentration of attention I.